ASH 2021 | Developing a score to predicting early relapse post-auto-HCT
Ibrahim Yakoub-Agha, MD, PhD, University of Lille, Lille, France, provides an overview of the development of a scoring system to predict early relapse following autologous hematopoietic cell transplantation (auto-HCT) in patients with myeloma. Patients who are at high risk of relapse can be offered alterative therapies and the scoring system has potential be used worldwide. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
Transcript (edited for clarity)
The chronic malignancies working party members have submitted more than 10 abstracts this year to the ASH. But as we discussed, we will pick up two of them. The first one, it’s regarding a new scoring system for early relapse after autologous transplantation in patients with multiple myeloma. So it’s kind of data mining, so what we wanted in this is to set up a very simple scoring system, so that we can identify patients at high risk of relapse after autologous transplantation...
The chronic malignancies working party members have submitted more than 10 abstracts this year to the ASH. But as we discussed, we will pick up two of them. The first one, it’s regarding a new scoring system for early relapse after autologous transplantation in patients with multiple myeloma. So it’s kind of data mining, so what we wanted in this is to set up a very simple scoring system, so that we can identify patients at high risk of relapse after autologous transplantation.
And we may offer them early new therapy or treatment, et cetera. So it’s something I would say will be helpful and simple so it can be used by all centers across the world, I would say. So this is a very important study. So we are looking forward to the submission and application of this with Professor Meral Beksac.
Read more...
